|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EHMK-51-35 carrier cells co-infected with AdE3-midkine and Ad-mGM-CSF induced a 100% complete tumor reduction in subcutaneous tumors and a 60% reduction of intraperitoneal disseminated tumors.
|
30548997 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma.
|
30773478 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3.
|
28102487 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, in in vitro and in vivo assays, knockdown of midkine resulted in significant sensitivity to anoikis, decreased cell survival and significantly decreased tumor occurrence rate.
|
28430645 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Midkine (MDK) is a tumor-promoting factor that is often overexpressed in various human carcinomas, and the role of MDK has not yet been fully investigated in prostate cancer stem cells.
|
28918838 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ALK activation was largely independent of mutations and correlated with midkine expression in tumors.
|
26687816 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Midkine overexpression has been shown to be a tumor biomarker in several types of human cancer, but little is known about the clinical significance of midkine in breast cancer patients.
|
26159850 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that MDKΔ81-121 dramatically inhibited (up to 91%) tumor development and growth.
|
25492619 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Treatment with trastuzumab inhibited tumor growth significantly in xenografts expressing MDK-HER2 fusion.
|
25889497 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We constructed replication-competent Ad5 of which the E1 region genes were activated by a transcriptional regulatory region of the midkine or the survivin gene, which is expressed preferentially in human tumors.
|
26059686 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Repository for Molecular Brain Neoplasia Data was analyzed to identify potential MDK regulators.
|
25428991 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Midkine is highly expressed in various cancers, including neuroblastoma, one of the most malignant paediatric solid tumours known.
|
24116381 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant positive correlation was observed between the expression levels of MK and the infiltrative depth of the tumor, the presence of lymph node metastasis and the prognosis of the patients (P<0.05).
|
25017879 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors.
|
23976985 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses.
|
23962292 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genetic ablation of midkine in this model delayed tumor formation and reduced tumor incidence.
|
23243020 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytokine midkine (MK) promotes tumor growth mainly by inducing angiogenesis.
|
22707563 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma.
|
22099874 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with high tumor midkine expression frequently have a worse prognosis than those with low expression.
|
22672821 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, MK serves as a tumor marker and a molecular target for cancer therapy.
|
22726064 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of midkine (MK), a heparin-binding growth factor, is increased in various human tumors, making it a promising tumor marker and target for tumor therapy.
|
21787488 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3.
|
21552147 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peptide-specific T cell lines recognized cells transfected with an MDK-encoded plasmid and tumor cell lines naturally expressing the MDK protein, but not untransfected cells.
|
20511550 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Midkine (MK) expression has been documented to be inversely correlated with the prognosis of patients with various tumors, but the mechanism of this relationship has not been well characterized.
|
20811700 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By contrast, no significant difference in cytotoxicity was detected between these viruses in normal human fibroblasts. oHSV-MDK-34.5 impaired in vivo tumor growth and increased median survival of MPNST tumor-bearing nude mice.
|
20603890 |
2010 |